Trial Profile
A Phase I Trial of Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs JCAR 015 (Primary) ; Cyclophosphamide; Pentostatin; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 09 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Sep 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 04 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.